Dengue Vaccine Candidate TAK-003 Looks Promising in Phase 3 Trial
The TIDES trial is investigating the safety and efficacy of 2 doses of TAK-003 in preventing dengue fever caused by any of the 4 dengue virus serotypes.
Dengue Fever
Dengue Vaccine Candidate Gets FDA’s Priority Review
Two Phase 3 trials conducted in Asia and Latin America assessed the efficacy of the vaccine in >35,000 individuals aged 2 to 16 years.
Dengue Detection and Preparedness Plan for 2020 Olympic Games in Tokyo
The failure mode and effect analysis methodology may facilitate protocols for new control that would benefit dengue detection and assessment for the 2020 Olympics.
Dengue Vaccine Presents Solutions and Backlash in Dengue-Endemic Regions
The principles of “trolleyology” can be used to understand hesitancy among certain individuals to vaccinate against the Dengue virus.
Zika Virus and Dengue Fever May Be Distinguished by Select Clinical Indicators
Diagnostic indicators including conjunctivitis, platelet count, and monocyte count can be used to reliably distinguish between Zika virus and dengue fever.
Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy
A tetravalent dengue vaccine protective against severe virologically confirmed dengue and hospitalization because of VCD for 5 years in patients with previous dengue exposure before vaccination.
Vector-Borne Diseases Up More Than 2-Fold From 2004 to 2016
Vector-borne diseases represent an increasing problem in the United States, with a more than 2-fold increase in the number of annual reports from 2004 to 2016.
Climate Change: Effects on the Incidence and Distribution of Infectious Diseases
Without proactive measures and response, the changing climate is projected to continue to adversely affect the global incidence and distribution of infectious diseases and cause 250,000 additional deaths per year between 2030 and 2050.
Rapid Antigen Test Differentiates Zika and Dengue Cases
A rapid immunochromatography approach can differentiate dengue and Zika virus cases
Second Dose of Tetravalent Dengue Vaccine Candidate Shows Enhanced Immunogenicity
A tetravalent dengue vaccine candidate (TDV) was found to be safe and immunogenic in an ongoing phase 2 trial. A second TDV dose induced enhanced immunogenicity against DENV-3 and DENV-4 in children who were seronegative before vaccination, supporting the initiation of phase 3 trial to evaluate the efficacy and safety of TDV given in a 2-dose schedule 3 months apart.
